Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/124033
Title: Pseudoprogression as an adverse event of glioblastoma therapy
Author: Balaña, Carmen
Capellades, Jaume
Pineda, Estela
Estival, Anna
Puig, Josep
Domenech, Sira
Verger, Eugènia
Pujol, Teresa
Martínez García, Maria
Oleaga, Laura
Velarde, Jose Maria
Mesia Barroso, Carlos
Fuentes, Rafael
Marruecos, Jordi
Barco, Sonia Del
Villà, Salvador
Carrato, Cristina
Gallego, Oscar
Gil Gil, Miguel
Craven Bartle, Jordi
Alameda, Francesc
GLIOCAT Group
Keywords: Tumors cerebrals
Brain tumors
Issue Date: 1-Dec-2017
Publisher: Wiley
Abstract: We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression (eP) or neither (nP). We examined potential associations with clinical, molecular, and basal imaging characteristics and compared overall survival (OS), progression-free survival (PFS), post-progression survival (PPS) as well as the relationship between PFS and PPS in the three groups. Of the 256 patients studied, 56 (21.9%) were classified as PsP, 70 (27.3%) as eP, and 130 (50.8%) as nP. Only MGMT methylation status was associated to PsP. MGMT methylated patients had a 3.5-fold greater possibility of having PsP than eP (OR: 3.48; 95% CI: 1.606-7.564; P=0.002). OS was longer for PsP than eP patients (18.9 vs. 12.3months; P=0.0001) but was similar for PsP and nP patients (P=0.91). OS was shorter-though not significantly sofor PsP than nP patients (OS: 19.5 vs. 27.9months; P=0.63) in methylated patients. PPS was similar for patients having PsP, eP or nP (PPS: 7.2 vs. 5.4 vs. 6.7; P=0.43). Neurological deterioration occurred in 64.3% of cases at the time they were classified as PsP and in 72.8% of cases of eP (P=0.14). PsP confounds the evaluation of disease and does not confer a survival advantage in glioblastoma.
Note: Reproducció del document publicat a: http://dx.doi.org/10.1002/cam4.1242
It is part of: Cancer Medicine, 2017, vol. 6, num. 12, p. 2858-2866
URI: http://hdl.handle.net/2445/124033
Related resource: http://dx.doi.org/10.1002/cam4.1242
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
cam4.1242.pdf187.33 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons